Search

Sort Results

Current filters: HIV drugs, HIV, Treatment, Raltegravir (Isentress, Isentress HD)

Isentress HD (raltegravir once daily): 2018, CATIE
Fact sheet - Webpage
Isentress (raltegravir twice daily): 2018, CATIE
Fact sheet - Webpage
CDC recommends use of raltegravir (Isentress) for PEP: From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage
Isentress HD in clinical trials: From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage
Isentress HD—a new once-daily formulation of raltegravir approved in Canada: From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage
Canadian researchers review the use of raltegravir in pregnancy: 2016, CATIE
Research summary - Webpage
U.S. study reviews use and impact of integrase inhibitors in pregnancy: 2016, CATIE
Research summary - Webpage
Comparing the tolerability and effectiveness of initial therapy: From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage
Dual therapy with raltegravir and darunavir: From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage
Raltegravir in women and reduced soluble CD14: From TreatmentUpdate 201
2014, CATIE
Research summary - Webpage